The Phase 3 Essence trial demonstrated that a once-weekly 2.4 mg dose of semaglutide effectively improved liver fibrosis and resolved steatohepatitis in NASH patients with stage 2 or 3 fibrosis ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Semaglutide (Wegovy ... In part 1 of the so-called ESSENCE trial, treatment with the GLP-1 receptor agonist resulted in higher week-72 rates of steatohepatitis resolution without worsening ...

Copyright: © 2025 Elsevier Ltd. Published by Elsevier Ltd. Semaglutide 2·4 mg once a week demonstrated significantly greater improvements in histology and fibrosis ...

Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomised Bagsværd, ...

Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomised Bagsværd ...